Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.50 |
| ▸ | CA2 | P00918 | 6/20 | 0.50 |
| ▸ | LMNA | P02545 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | PKM | P14618 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6087608 | 0.87 | SMN1; SMN2 (0.65) | CA1CA2LMNASMN1; SMN2HTT | |
| Batabulin SCHEMBL18845 | 0.85 | LMNA (0.54) | CA1CA2LMNASMN1; SMN2HTT | |
| Batabulin SCHEMBL29373304 | 0.85 | LMNA (0.54) | CA1CA2LMNASMN1; SMN2HTT | |
| Batabulin SCHEMBL6089508 | 0.84 | LMNA (0.53) | CA1CA2LMNASMN1; SMN2HTT | |
| Batabulin SCHEMBL6086887 | 0.84 | LMNA (0.53) | CA1CA2LMNASMN1; SMN2HTT | |
| SCHEMBL6087510 | 0.83 | LMNA (0.55) | CA1CA2LMNASMN1; SMN2HTT | |
| SCHEMBL6086804 | 0.83 | MEN1 (0.62) | LMNASMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL6089371 | 0.83 | CA1 (0.50) | CA1CA2LMNASMN1; SMN2HTT | |
| SCHEMBL22909408 | 0.82 | LMNA (0.49) | CA1CA2LMNASMN1; SMN2HTT | |
| SCHEMBL6088076 | 0.82 | CA1 (0.49) | CA1CA2LMNASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0939627-B1 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK INC (US) | 2003-09-10 | — | — | EP | claimed |
| US-20030162817-A1 | Pentafluorobenzenesulfonamides and analogs | TULARIK INC. | 2003-08-28 | — | — | US | claimed |
| JP-3421350-B2 | — | — | 2003-06-30 | — | — | JP | claimed |
| US-6482860-B1 | such as batabulin (2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene), use as antiproliferative agents to treat cancer | TULARIK INC. | 2002-11-19 | — | — | US | claimed |
| US-20020143036-A1 | Pentafluorobenzenesulfonamides and analogs | TULARIK INC. | 2002-10-03 | — | — | US | claimed |
| JP-2000515545-A | — | — | 2000-11-21 | — | — | JP | claimed |
| EP-0939627-A4 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK INC (US) | 2000-10-04 | — | — | EP | claimed |
| EP-0939627-A1 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK, INC. (US) | 1999-09-08 | — | — | EP | claimed |
| EP-0896533-A4 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK INC (US) | 1999-04-28 | — | — | EP | claimed |
| US-5880151-A | TREATING OR PREVENTING DISEASE CHARACTERIZED BY HIGH LEVELS OF LOW DENSITY LIPOPROTEIN PARTICLES OR CHOLESTEROL IN BLOOD | TULARIK INC. (US) | 1999-03-09 | — | — | US | claimed |
| EP-0896533-A2 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK, INC. (US) | 1999-02-17 | — | — | EP | claimed |
| WO-1998005315-A1 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK, INC. (US) | 1998-02-12 | — | — | WO | claimed |
| WO-1997030677-A2 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK, INC. (US) | 1997-08-28 | — | — | WO | claimed |
| US-7138418-B2 | For therapy of atherosclerosis and hypercholesterolemia; 5-Pentafluorophenylsulfonamidoindazole for example; increasing LDL receptor gene expression in a cell | AMGEN, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-7060718-B2 | Arylsulfonanilide ureas | AMGEN INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-6962929-B2 | Pentafluorobenzenesulfonamides and analogs | TULARIK INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-5880151-A | TREATING OR PREVENTING DISEASE CHARACTERIZED BY HIGH LEVELS OF LOW DENSITY LIPOPROTEIN PARTICLES OR CHOLESTEROL IN BLOOD | TULARIK INC. (US) | 1999-03-09 | — | — | US | disclosed |
| EP-0896533-A2 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK, INC. (US) | 1999-02-17 | — | — | EP | disclosed |
| WO-1998005315-A1 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| WO-1997030677-A2 | PENTAFLUOROBENZENESULFONAMIDES AND ANALOGS | TULARIK, INC. (US) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162817-A1 | Pentafluorobenzenesulfonamides and analogs | FGFR1, FPR1, FGF1 | CA1 3297/4885CA2 3367/4885LMNA 4425/4885 |
| US-20020143036-A1 | Pentafluorobenzenesulfonamides and analogs | FFAR1, PCSK9, PFAS | CA1 2017/4885CA2 3421/4885LMNA 2277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.